Life sciences business OptiBiotix has filed a patent for a product which combats infections caused by superbugs such as MRSA. York-based OptiBiotix Health, which develops compounds to tackly obesity, high cholesterol and diabetes, has developed microbial proteins to fight superbug infections (also known as Health Care Acquired Infections or HCAIs). HCAIs lead to higher morbidity and mortality, and cost the NHS an estimated £1bn per year.
Stephen O’Hara, CEO of OptiBiotix, said: “These proteins prevent skin damage, stop pathogenic bacteria from growing, and most importantly prevent it from reattaching, reducing the risk of reinfection with AMR superbugs.”
See the article in full at BusinessDesk.com